A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia

European Archives of Oto-Rhino-Laryngology

Volumn 269, Issue 2, 2012, Pages 531-536

  Rohrmeier, C ^a   Sachs, H G ^b   Kuehnel, T S ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Avastin; Bevacizumab; Epistaxis; Hereditary haemorrhagic telangiectasia (HHT); Retrospective; VEGF

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DISEASE SEVERITY; EPISTAXIS; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NEODYMIUM LASER; NOSE MUCOSA; PRIORITY JOURNAL; QUESTIONNAIRE; RENDU OSLER WEBER DISEASE; RETROSPECTIVE STUDY; SUBMUCOSA;

ADMINISTRATION, INTRANASAL; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD TRANSFUSION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPISTAXIS; FEMALE; HEMOGLOBINOMETRY; HUMANS; INJECTIONS, INTRALESIONAL; LASER COAGULATION; MALE; MICROSURGERY; MIDDLE AGED; NEOADJUVANT THERAPY; OFF-LABEL USE; RETROSPECTIVE STUDIES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84857038767     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-011-1721-9     Document Type: Article

References (30)

1. UW Geisthoff G Schneider J Fischinger PK Plinkert 2002 Hereditäre hämorrhagische Teleangiektasie (Morbus Osler) HNO 50 114 128 12080621 10.1007/s001060100537 1:STN:280:DC%2BD38zjvVGisQ%3D%3D
2. JE McDonald FJ Miller SE Hallam L Nelson DA Marchuk KJ Ward 2000 Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred Am J Med Genet 93 320 327 10946360 10.1002/1096-8628(20000814)93: 4<320::AID-AJMG12>3.0.CO;2-R 1:STN:280:DC%2BD3M3osVegug%3D%3D
3. FS Govani CL Shovlin 2009 Hereditary haemorrhagic telangiectasia: a clinical and scientific review Eur J Hum Genet 17 860 871 19337313 10.1038/ejhg.2009.35 1:CAS:528:DC%2BD1MXnsFCgu7Y%3D
4. CL Shovlin AE Guttmacher E Buscarini, et al. 2000 Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) Am J Med Genet 91 66 67 10751092 10.1002/(SICI)1096-8628(20000306)91:1<66::AID- AJMG12>3.0.CO;2-P 1:STN:280:DC%2BD3c3htlWntg%3D%3D
5. F Pagella A Colombo E Matti, et al. 2009 Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients Am J Rhinol Allergy 23 52 58 19379613 10.2500/ajra.2009.23.3263
6. BJ Folz B Zoll H Alfke A Toussaint RF Maier JA Werner 2006 Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents Eur Arch Otorhinolaryngol 263 53 61 15976991 10.1007/s00405-005-0956-8
7. E Yaniv M Preis T Hadar J Shvero M Haddad 2009 Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial Laryngoscope 119 284 288 19160429 10.1002/lary.20065 1:CAS:528:DC%2BD1MXntFWks70%3D
8. L Fernandez EM Garrido-Martin F Sanz-Rodriguez, et al. 2007 Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells Thromb Haemost 97 254 262
9. VJ Lund DJ Howard 1996 Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic teleangiectasia J Laryngol Otol 111 30 33
10. RJ Harvey J Kanagalingam VJ Lund 2008 The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis Am J Rhinol 22 182 187 18416977 10.2500/ajr.2008.22.3145
11. I Karapantzos N Tsimpiris DG Goulis H Van Hoecke P Van Cauwenberge V Danielides 2005 Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire Eur Arch Otorhinolaryngol 262 830 833 15739086 10.1007/s00405-004-0911-0
12. H Sadick J Hage U Goessler, et al. 2008 Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF? Int J Mol Med 22 575 580 18949376 1:CAS:528:DC%2BD1cXhsVahsbzI
13. H Sadick F Riedel R Naim, et al. 2005 Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression Haematologica 90 818 828 15951295 1:CAS:528:DC%2BD2MXnvVWku7Y%3D
14. A Cirulli A Liso F D'Ovidio, et al. 2003 Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia Acta Haematol 110 29 32 12975554 10.1159/000072411 1:CAS:528:DC%2BD3sXntlShu7c%3D
15. SK Mukherji 2010 Bevacizumab (Avastin) AJNR 31 235 236 20037132 10.3174/ajnr.A1987 1:STN:280:DC%2BC3c7gtVOqsA%3D%3D
16. JS Thompson Coon Z Liu M Hoyle, et al. 2009 Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness Br J Cancer 101 238 243 19568242 10.1038/sj.bjc.6605167 1:CAS:528:DC%2BD1MXoslOmtbc%3D
17. S Sacu S Michels F Prager, et al. 2009 Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results Eye (Lond) 23 2223 2227 10.1038/eye.2008.423 1:CAS:528:DC%2BD1MXhsFekurjI
18. JB Hoag P Terry S Mitchell D Reh CA Merlo 2010 An epistaxis severity score for hereditary hemorrhagic telangiectasia Laryngoscope 120 838 843 20087969 10.1002/lary.20818
19. TS Kuehnel BH Wagner CP Schurr J Strutz 2005 Clinical strategy in hereditary hemorrhagic telangiectasia Am J Rhinol 19 508 513
20. HF Dvorak LF Brown M Detmar AM Dvorak 1995 Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis Am J Pathol 146 1029 1039 7538264 1:CAS:528:DyaK2MXmt1Kkt7g%3D
21. B Folz AC Wollstein BM Lippert JA Werner 2005 Morphology and distribution of nasal telangiectasia in hht-patients with epistaxis Am J Rhinol 19 70 75 (6)
22. J Simonds F Miller J Mandel TM Davidson 2009 The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia Laryngoscope 119 988 992 19194865 10.1002/lary.20159 1:CAS:528: DC%2BD1MXntFWltLg%3D
23. LM Randall BJ Monk 2010 Bevacizumab toxicities and their management in ovarian cancer Gynecol Oncol 117 497 504 20363017 10.1016/j.ygyno.2010.02.021 1:CAS:528:DC%2BC3cXmtFajtr4%3D
24. TT Karnezis TM Davidson 2011 Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis Laryngoscope 121 636 638 21344445 10.1002/lary.21415 1:CAS:528:DC%2BC3MXjt1Wrsbw%3D
25. F Retornaz Y Rinaldi C Duvoux 2009 More on bevacizumab in hereditary hemorrhagic telangiectasia N Engl J Med 361 931 932 19714790 10.1056/NEJMc091271 1:CAS:528:DC%2BD1MXhtVKhtb3L
26. S Oosting W Nagengast E de Vries 2009 More on bevacizumab in hereditary hemorrhagic telangiectasia N Engl J Med 361 931 932 19710496 10.1056/NEJMc091271 1:CAS:528:DC%2BD1MXhtVKhtb3K
27. P Bose JL Holter GB Selby 2009 Bevacizumab in hereditary hemorrhagic telangiectasia N Engl J Med 360 2143 2144 19439755 10.1056/NEJMc0901421 1:CAS:528:DC%2BD1MXlvF2iurk%3D
28. D Flieger S Hainke W Fischbach 2006 Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab Ann Hematol 85 631 632 16807748 10.1007/s00277-006-0147-8
29. P Bose JL Holter GB Selby 2009 More on bevacizumab in hereditary hemorrhagic telangiectasia N Engl J Med 361 931 932 10.1056/NEJMc091271 1:CAS:528:DC%2BD1MXhtVKhtb3F
30. TM Davidson SE Olitsky JL Wei 2010 Hereditary hemorrhagic telangiectasia/avastin Laryngoscope 120 432 435 19998344